GlassScriptPhysician profile
Julia H Cohen
NPI 1659464352
$8,419.85
in general payments reported to CMS, 2019-2025
30 companies · $850 in 2025
The $850 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,396 · 2020: $580 · 2021: $697 · 2022: $1,481 · 2023: $1,598 · 2024: $1,818 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,266.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,547.68 | 2019-2025 | Tremfya, Remicade, Stelara |
| Abbvie INC. | $1,316.37 | 2019-2025 | Skyrizi, Rinvoq |
| Amgen INC. | $662.20 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $568.18 | 2019-2025 | |
| Lilly USA, LLC | $452.42 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $441.15 | 2019-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $389.33 | 2019-2025 | Dupixent |
| Incyte Corporation | $327.32 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $325.89 | 2019-2025 | Aklief, Epsolay |
| Genzyme Corporation | $313.65 | 2019-2024 | |
| Leo Pharma INC. | $274.58 | 2020-2024 | Adbry |
| Sun Pharmaceutical Industries INC. | $257.45 | 2019-2025 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $234.35 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $209.75 | 2023-2024 | Zoryve |
| Dermavant Sciences, INC. | $205.51 | 2023-2024 | Vtama |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $204.39 | 2019 | |
| Pfizer INC. | $161.05 | 2020-2024 | |
| Mayne Pharma Commercial LLC | $108.26 | 2019-2025 | |
| Genentech USA, INC. | $71.76 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $62.14 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $58.80 | 2020-2021 | |
| Almirall LLC | $41.51 | 2024 | Klisyri, Seysara |
| Dermira, INC. | $38.26 | 2019 | |
| Encore Dermatology INC. | $27.57 | 2019-2020 | |
| Mission Pharmacal Company | $26.91 | 2021 | |
| Epi Health, LLC | $25.03 | 2022 | |
| Promius Pharma LLC | $22.62 | 2019 | |
| Lnhc, INC | $16.95 | 2025 | Zelsuvmi |
| Organon LLC | $15.40 | 2025 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $13.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.